HYTN enters arrangement agreement for peptide drug development spin-out
HYTN Innovations Inc. says it has entered into an arrangement agreement to facilitate the spin-out of a peptide-focused drug development business.
VANCOUVER, British Columbia, Sept.
02, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC Pink: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, announces that it has entered into an a…